References - CKD Change Package

  1. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet. In: U.S. Department of Health and Human Services, ed. Atlanta, GA: Centers for Disease Control and Prevention,; 2017.
  2. Szczech LA, Stewart RC, Su HL, et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PloS one 2014;9:e110535.
  3. United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. In. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2016.
  4. Golestaneh L, Alvarez PJ, Reaven NL, et al. All-Cause Costs Increase Exponentially with Increased Chronic Kidney Disease Stage. American Journal of Managed Care 2017;23:S0.
  5. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD; 2013.
  6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-y. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. New England Journal of Medicine 2004;351:1296-305.
  7. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. The Lancet Diabetes & Endocrinology;3:514-25.
  8. Narva A. Population Health for CKD and Diabetes: Lessons From the Indian Health Service. American Journal of Kidney Diseases.
  9. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002;39:S1-S266.
  10. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD. Practical Approach to Detection and Management of Chronic Kidney Disease for the Primary Care Clinician. The American Journal of Medicine;129:153-62.e7.
  11. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018;71:e13-e115.
  12. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Jama 2003;289:2560-72.
  13. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (jnc 8). Jama 2014;311:507-20.
  14. Taler SJ, Agarwal R, Bakris GL, et al. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. American Journal of Kidney Diseases;62:201-13.
  15. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney International 1996;50:1651-8.
  16. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). Journal of the Renin-Angiotensin-Aldosterone System 2000;1:328-35.
  17. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New England Journal of Medicine 2001;345:851-60.
  18. Wright, Jr JT, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the aask trial. Jama 2002;288:2421-31.
  19. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases;60:850-86.
  20. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.
  21. 2010 Chronic Kidney Disease (CKD) Evidence-Based Nutrition Practice Guideline (Accessed May 24, 2018, at
  22. Kramer H, Jimenez EY, Brommage D, et al. Medical Nutrition Therapy for Patients with Non-Dialysis-Dependent Chronic Kidney Disease: Barriers and Solutions. Journal of the Academy of Nutrition and Dietetics 2018;118:1958-65.
  23. Friedewald VE, Bennett JS, Christo JP, et al. Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. American Journal of Cardiology 2010;106:873-84.
  24. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonsteroidal anti‐inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiology and Drug Safety 2012;21:1155-72.
  25. Arora P, Elkin PL, Eberle J, et al. An observational study of the quality of care for chronic kidney disease: a Buffalo and Albany, New York metropolitan area study. BMC Nephrology 2015;16:199.
  26. Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H. Outcomes in Patients with Chronic Kidney Disease Referred Late to Nephrologists: A Meta-analysis. The American Journal of Medicine 2007;120:1063-70.e2.
  27. Bullock A, Burrows NR, Narva AS, et al. Vital Signs: Decrease in Incidence of Diabetes-Related End-Stage Renal Disease among American Indians/Alaska Natives — United States, 1996–2013. Atlanta; 2017.
  28. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92.
  29. Slinin Y, Guo H, Gilbertson DT, et al. Prehemodialysis Care by Dietitians and First-Year Mortality After Initiation of Hemodialysis. American Journal of Kidney Diseases 2011;58:583-90.
  30. Wei L, MacDonald TM, Jennings C, Sheng X, Flynn RW, Murphy MJ. Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function. Kidney International;84:174-8.
  31. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. Jama 2011;305:1553-9.
  32. Mendu ML, Schneider LI, Aizer AA, et al. Implementation of a CKD Checklist for Primary Care Providers. Clinical Journal of the American Society of Nephrology 2014;9:1526-35.
  33. Fox CH, Vest BM, Kahn LS, et al. Improving evidence-based primary care for chronic kidney disease: study protocol for a cluster randomized control trial for translating evidence into practice (TRANSLATE CKD). Implementation Science 2013;8:88.
  34. Sequist TD, Holliday AM, Orav J, Bates DW, Denker BM. Physician and patient tools to improve chornic kidney disease care. Am J Manag Care 2018;24:e107-e14.
  35. Drawz PE, Archdeacon P, McDonald CJ, et al. CKD as a Model for Improving Chronic Disease Care through Electronic Health Records. Clinical Journal of the American Society of Nephrology 2015;10:1488-99.
  36. Litvin CB, Hyer JM, Ornstein SM. Use of Clinical Decision Support to Improve Primary Care Identification and Management of Chronic Kidney Disease (CKD). The Journal of the American Board of Family Medicine 2016;29:604-12.
  37. Wentworth A, L.,, Fox CH, Kahn LS, Glaser K, Cadzow R. Two Years After a Quality Improvement Intervention for Chronic Kidney Disease Care in a Primary Care Office. American Journal of Medical Quality 2011;26:200-5.
  38. Lee B, Turley M, Meng D, et al. Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis. BMC Health Services Research 2012;12:252.
  39. URL Resources
  85. 84.